Advertisement

Nicardipine Notes

Fatal Forty DDI: nicardipine, tacrolimus, CYP3A4

Abstract

This case discusses an interaction between tacrolimus and nicardipine. Tacrolimus is a cytochrome P450 3A4 substrate and nicardipine is a 3A4 inhibitor. The interaction resulted in tacrolimus toxicity. The pharmacokinetics of nicardipine are also discussed.

Keywords

Pharmacokinetic Inhibition Inhibitor CYP3A CYP3A4 CYP3A5 3A 3A4 3A5 Cytochrome P450 Transplant Immunosuppressant Tacrolimus Nicardipine Nifedipine Dihydropyridine calcium channel antagonist Calcineurin inhibitor Therapeutic drug monitoring 

References

  1. 1.
    Amundsen R, Asberg A, Ohm I, et al. Cyclosporine A and tacrolimus mediated inhibition of cytochrome P450 3A4 and 3A5 in vitro. Drug Metab Dispos. 2011. [Epub ahead of print].Google Scholar
  2. 2.
    Hooper D, Carle A, Schuchter J, et al. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011;15:88–95.PubMedCrossRefGoogle Scholar
  3. 3.
    Katoh M, Nakajima M, Shimada N, et al. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55:843–52.PubMedCrossRefGoogle Scholar
  4. 4.
    LeCointre K, Furlan V, Taburet A. In vitro effects of tacrolimus on human cytochrome P450. Fundam Clin Pharm. 2022;16:455–60.CrossRefGoogle Scholar
  5. 5.
    Roth S, Munoz R, Schmitt C, et al. Vasodilators. In: Munoz R, Schmitt C, Roth S, editors. Handbook of pediatric cardiovascular drugs. London: Springer; 2008. p. 77–119.CrossRefGoogle Scholar
  6. 6.
    Zangar R, Okita J, Kim H, et al. Effect of calcium channel antagonists nifedipine and nicardipine on rat cytochrome P-450 2B and 3A Forms. J Pharmacol Exp Ther. 1999;290:1436–41.PubMedGoogle Scholar
  7. 7.
    Zhou S, Xue C, Yu X, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29:687–710.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of AnethesiologyBaylor College of MedicineHoustonUSA
  2. 2.Department of AnesthesiologyUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations